Üçlü Negatif Meme Kanseri Hastalarında Neoadjuvan Kemoterapiye Yanıt ve Prognoz ile Fhit İfadesi Arasındaki İlişkinin Araştırılması
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Tekirdağ Namık Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Meme kanseri dünya genelinde kadınlarda en sık görülen ve ölüm oranı en fazla olan kanser türüdür. Üçlü negatif meme kanseri (TNBC), en agresif ve prognozu kötü meme kanseri alt tipidir. Östrojen, progesteron ve HER2 reseptörü ifadesi olmadığından hedefli bir tedavi tanımlanmamıştır. Bu nedenle bugün sadece kemoterapiyle tedavi edilebilmektedir. Neoadjuvan tedavi ile nüks riskinin azaltılması, cerrahi müdahale şansının artırılması, cerrahi sonrası komplikasyon riskinin azaltılması ve hayat kalitesinin artırılması sağlanmaktadır. TNBC neoadjuvan kemoterapiye en iyi tümöral, nodal ve patolojik tam yanıt pCR veren alt gruplardan biridir. Bu çalışmanın amacı TNBC hastalarında Fhit ifadesinin hem neoadjuvan kemoterapiye yanıt hem de klinik patolojik verilerle ilişkisini araştırmaktır. FHIT, FRA3B frajil bölgede olup tümör baskılayıcı gendir. Meme kanserinde sıklıkla Fhit ifade kaybı görülmektedir. Çalışmaya TNBC'li 50 hasta dahil edildi. Parafin bloklu preparatlarda Fhit ifadesi immünohistokimyasal (IHC) olarak değerlendirildi. İfade yüzdeleri ve skorları, klinik patolojik ve sağkalım verileri ile karşılaştırıldı. Fhit ifade kaybının görüldüğü hastalarda, T evresinin arttığı belirlendi ve istatistiksel olarak anlamlı bulundu (p=0,003). Çalışmamızda Fhit ifadesinin TNBC'de, T evresi dışındaki klinik patolojik ve prognostik faktörlerle anlamlı ilişkisi bulunmadı (p>0,05). Ancak Fhit ifade kaybının genel sağkalım üzerine negatif korelasyonda prognostik belirteç olabileceği gösterildi. Fhit ifade kaybıyla TNBC ilişkisinin daha net ortaya konulabilmesi için ileri çalışmalar gerekmektedir. Çalışmamızdan elde ettiğimiz sonuçlar literatürle uyumlu olup yeni verilerle alana katkı sağlayacak ve bu konudaki gelecekteki araştırmalara ışık tutacak niteliktedir.
Breast cancer is the most common type of cancer in women worldwide and has the highest mortality rate. The most aggressive type of cancer is triple negative breast cancer (TNBC), which is a poorly prognostic subtype of breast cancer. Estrogen, progesterone, and HER2 receptor expression are absent and an option of targeted therapy is not available. Therefore, currently it can only be treated with chemotherapy. With the neoadjuvant treatment, it is aimed to reduce the risk of recurrence, to increase the chance of surgical intervention, to reduce the risk of complications after surgery and to increase the quality of life. TNBC is one of the subgroups with the best tumoral, nodular and pathological response to neoadjuvant chemotherapy. In this study, it was aimed to show the relationship both between the response to neoadjuvant chemotherapy and Fhit expression and between Fhit expression and clinical pathological data in TNBC patients. FHIT is a tumor suppressor gene located in the fragile region of FRA3B. Loss of Fhit expression is frequently seen in breast cancer. 50 patients with TNBC were included in the study. Fhit expression in formalin-fixed parafine-embedded (FFPE) blocks was evaluated immunohistochemically (IHC). Fhit expression percentages and scores were in comparison with clinical pathological and survival data. T-stage was found to increase in patients with loss of Fhit expression and it was statistically significant (p=0.003). In our study, the relationship between Fhit expression in TNBC and clinical pathological and prognostic factors, other than T stage, could not be significantly demonstrated (p>0.05). However, loss of Fhit expression may be a negative prognostic marker for overall survival. Larger-scale studies are needed to elucidate the relationship between Fhit expression loss and TNBC. The results we obtained from our study are compatible with the literature and will contribute to the field with new data and shed light on future research on this subject.
Breast cancer is the most common type of cancer in women worldwide and has the highest mortality rate. The most aggressive type of cancer is triple negative breast cancer (TNBC), which is a poorly prognostic subtype of breast cancer. Estrogen, progesterone, and HER2 receptor expression are absent and an option of targeted therapy is not available. Therefore, currently it can only be treated with chemotherapy. With the neoadjuvant treatment, it is aimed to reduce the risk of recurrence, to increase the chance of surgical intervention, to reduce the risk of complications after surgery and to increase the quality of life. TNBC is one of the subgroups with the best tumoral, nodular and pathological response to neoadjuvant chemotherapy. In this study, it was aimed to show the relationship both between the response to neoadjuvant chemotherapy and Fhit expression and between Fhit expression and clinical pathological data in TNBC patients. FHIT is a tumor suppressor gene located in the fragile region of FRA3B. Loss of Fhit expression is frequently seen in breast cancer. 50 patients with TNBC were included in the study. Fhit expression in formalin-fixed parafine-embedded (FFPE) blocks was evaluated immunohistochemically (IHC). Fhit expression percentages and scores were in comparison with clinical pathological and survival data. T-stage was found to increase in patients with loss of Fhit expression and it was statistically significant (p=0.003). In our study, the relationship between Fhit expression in TNBC and clinical pathological and prognostic factors, other than T stage, could not be significantly demonstrated (p>0.05). However, loss of Fhit expression may be a negative prognostic marker for overall survival. Larger-scale studies are needed to elucidate the relationship between Fhit expression loss and TNBC. The results we obtained from our study are compatible with the literature and will contribute to the field with new data and shed light on future research on this subject.
Açıklama
Sağlık Bilimleri Enstitüsü, Tıbbi Genetik Ana Bilim Dalı
Anahtar Kelimeler
Patoloji, Pathology ; Tıbbi Biyoloji
